COMMUNIQUÉS West-GlobeNewswire

Transactions in connection with share buy-back program
27/10/2026
Company announcement no. 43 - 26 27 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Newsweek classe le KFSH parmi les 4 % d’hôpitaux les plus avancés au monde en matière de maturité numérique et d’IA
27/10/2026
RIYAD, Arabie saoudite, 27 oct. 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) est l’un des 15 seuls hôpitaux au monde à avoir obtenu à la fois la note maximale de cinq rubans [...]
Immuron continued quarterly sales growth
27/10/2026
Sales Highlights (unaudited): Global Q1 sales AUD$2.2 million up 9% on prior comparative period (pcp) Q1 sales up 5% on prior quarter Australia Q1 sales AUD$1.8 million up 14% on prior comparative period (pcp) Q1 sales [...]
Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
27/10/2026
SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended [...]
Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium
27/10/2026
Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeutics SEATTLE, [...]
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
27/10/2026
- Results Demonstrated Breadth and Rapidity of Response to ATI-052 in Heterogeneous Patient Populations; Pharmacodynamic Results Demonstrated Potential for Additivity/Synergy of Targeting TSLP and IL-4R α - - Rapid and [...]
Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026
27/10/2026
MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) today announced that Azeem Latib, MD, will present the first [...]
Merakris Advances Potentially Pivotal MTX-001 Phase 2/3 Strategy Following FDA Pre-IND Meeting
27/10/2026
FDA indicates proposed double-blind Phase 2/3 design could be considered adequate and well controlled as Merakris prepares its first commercial-pilot GMP drug lot for a potentially pivotal trial. RESEARCH TRIANGLE PARK [...]
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
27/10/2026
WAYNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
27/10/2026
Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations RUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025 [...]
Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance
27/10/2026
Ad hoc announcement pursuant to Art. 53 LR Third quarter Q3 net sales grew +4% (cc ¹ , +4% USD), with core operating income ¹ +10% (cc, +11% USD) Sales growth driven by priority brands including Kisqali (+37% cc), [...]
Basilea raises full-year guidance 2026 and financial target for “Agenda 2030” and provides updates on late-stage clinical programs
27/10/2026
2026 operating profit expected to reach CHF 115 million (previously CHF 70 million) driven by higher than expected Cresemba and Zevtera-related revenue of CHF 250 million (previously CHF 210 million) Cumulative cash [...]
Idorsia seeks US label update for QUVIVIQ daytime functioning benefits – first patients enrolled in Dari-Dream
27/10/2026
Building on established clinical evidence, Dari-Dream is designed to further characterize the impact of QUVIVIQ on daytime functioning and support its inclusion in the US prescribing information. Allschwil, Switzerland [...]
Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories
27/10/2026
The cobas smart e immunoanalyser – the newest addition to Roche’s industry-leading cobas immunoassay systems portfolio – is engineered to deliver central-lab performance in a footprint under one square metre. With a [...]
ONWARD Medical to Announce Third-Quarter 2026 Results on November 3, 2026
27/10/2026
EINDHOVEN, The Netherlands, Oct. 27, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and [...]
Major shareholder announcement
27/10/2026
Company announcement no. 42 - 26 27 October 2026 Notification of holding of treasury shares Pursuant to Section 31 of the Danish Capital Markets Act, it is hereby announced that as of 26 October 2026, NTG Nordic [...]
Purespring Therapeutics advances kidney-targeted gene therapy PS-003 towards the clinic in X-linked Alport Syndrome, with new preclinical and epidemiological data presented at ASN Kidney Week 2026
27/10/2026
PS-003 is designed to address the underlying genetic cause of X-linked Alport Syndrome (XLAS), and new preclinical data demonstrate the restoration of COL4A5, the key collagen protein absent or defective in X LAS PS-003 [...]
KFSH Strengthens Patient-Centered Care With ICHOM Accreditation
27/10/2026
RIYADH, Saudi Arabia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has earned Level 1 accreditation from the International Consortium for Health Outcomes Measurement ( [...]
Cellectis présente de nouvelles données précliniques démontrant une édition efficace du gène APOC3 et une réduction marquée des triglycérides avec .HEAL-101 à l’ESGCT 2026
27/10/2026
Un taux d’édition in vivo du gène APOC3 humain atteignant 70% après une seule administration Une réduction de 76 % du taux de triglycérides après une dose unique dans un modèle murin de la maladie NEW YORK, 27 oct. 2026 [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum